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1. Introduction 
Chemotherapy is often used in the conservative management of retinoblastoma. 
Chemotherapy drugs, while ameliorative, can produce long-lasting side effects that 
potentially can affect survivor quality of life.  Carboplatin is a common chemotherapy agent 
with known ototoxic side effects that is used in the treatment of retinoblastoma (Rodriguez-
Galindo et al., 2003). The potential for carboplatin-induced hearing loss is of concern to the 
medical professional, given that retinoblastoma is often diagnosed in early childhood and 
children with retinoblastoma have visual impairments. This chapter will outline the 
mechanisms underlying carboplatin ototoxicity. The extent of knowledge concerning the 
pathophysiology of carboplatin-induced hearing loss will be explained, and descriptions of 
the progression of hearing loss on the audiogram will be provided. The types of hearing 
tests administered to patients receiving carboplatin chemotherapy and monitoring regimens 
will be reviewed in the chapter. Physiological hearing tests, including the auditory 
brainstem response (ABR) and otoacoustic emissions (OAE) will be described. Knowledge 
of these tests will assist the medical professional in understanding if a particular 
chemotherapy regimen is potentially causing a hearing loss.  
The impact of high-frequency hearing loss on the development of speech and language in 
young children will be discussed, which is of particular relevance in children with an 
existing visual loss. In the context of this discussion, the academic and social development of 
children with hearing loss will be addressed. Future directions, including the potential use 
of otoprotective agents that can be given concurrently with chemotherapy treatment, will be 
highlighted at the end of the chapter.  
2. Pathophysiology of carboplatin-induced hearing loss 
Carboplatin (cis-diammine [1,1-cyclobutanedicarboxylate]-platinum [II]) is a second-
generation platinum compound that initially was reported to have less nephrotoxic and 
ototoxic side effects than its analog, cisplatin (Bacha et al., 1986). It is a common 
chemotherapy agent used in the treatment of a wide range of pediatric malignancies.  More 
recently, higher incidences of carboplatin ototoxicity have been reported compared with 
what was previously described in the literature. The pathophysiology of carboplatin 
ototoxicity is not completely understood, but evidence from experimental animal models 
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suggests dose-dependent and species-specific effects of carboplatin. Chinchillas are rodents 
that are commonly used as animal models in experimental studies. In chinchillas, 
administration of low doses of carboplatin results in the progressive loss of inner hair cells 
and spiral ganglion neurons from the apex to the base of the cochlea, and outer hair cells are 
largely unaffected (Takeno et al., 1994; Hofstetter et al., 1997a; Wang et al., 2003; Bauer & 
Brozoski, 2005). At higher doses of carboplatin, extensive loss of inner hair cells is exhibited 
across all cochlear turns, and loss of outer hair cells is exhibited most prominently in the 
basal turn (Hofstetter et al., 1997a; Bauer & Brozoski, 2005). Studies of high-dose carboplatin 
administration in guinea pigs revealed that primarily outer hair cells were destroyed (Saito 
et al., 1989), and both outer and inner hair cells were affected in rats (Husain et al., 2001). 
3. Methods of hearing assessment in young children 
Retinoblastoma is one of the most common intraocular malignancies in young children 
and it is usually diagnosed before children reach three years of age (Broaddus et al., 2009). 
Until recently, suspicion of childhood hearing loss was primarily based on behavioral 
observations by physicians or anecdotes provided by concerned parents. However, 
reliance on behavioral observations is often confounded by the fact that hearing-impaired 
infants often seemingly respond to environmental sounds and can babble in a manner 
similar to normal-hearing infants (Marschark, 1997). These factors often resulted in delays 
in identifying children with hearing loss. In the past, the typical age of identification of 
hearing loss in the United States was 11-19 months for children with risk factors for 
hearing loss and 15-19 months for children with no known risk factors (Mauk et al., 1991; 
Parving ,1993; Stein, 1995; Harrison & Roush, 1996). In the United Kingdom, the average 
age of suspicion of hearing loss was 18.8 months and hearing loss was confirmed at an 
average age of 26 months (Davis et al., 1997). It is crucial that young children with 
retinoblastoma experiencing vision loss be monitored appropriately while they undergo 
chemotherapy, as undetected ototoxic hearing loss can impact the development of speech 
and language.  
Hearing is a complex psychological process involving the detection, identification, and 
comprehension of sound. Assessment of hearing in infants and young children has evolved 
from reliance primarily on behavioral observations alone to combining behavioral 
observations with computer-based measurements of auditory physiology. As infants and 
young children often cannot respond reliably during behavioral hearing assessments, 
modification of the testing protocol often includes physiological tests of auditory function.  
While physiological measurements do not test the psychological aspects of hearing directly, 
they provide information on the status of anatomical structures believed to be crucial for 
hearing. The major advantage of these physiological tests is that they do not require a 
behavioral response from the infant, and can be completed rapidly. Most importantly for 
screening purposes, physiological test results are highly informative in distinguishing 
between normal-hearing infants and infants with hearing loss. The Joint Committee on 
Infant Hearing recommended inclusion of ABR and/or OAE tests in screening programs 
designed to detect hearing loss in infants (Joint Committee on Infant Hearing, 2000). 
Although these tests are not true tests of hearing, they may provide evidence of a change in 
cochlear function during the administration of potentially ototoxic medications including 
carboplatin.  
www.intechopen.com
 
Ototoxic Hearing Loss and Retinoblastoma Patients 
 
41 
Study 
Behavioral 
Audiometry 
ABR OAE 
# of patients 
studied 
Smits et al. (2006) Yes Yes Yes 25 
Lambert et al. 
(2008) 
Yes Yes No 164 
Jehanne et al. 
(2009) 
Yes No No 175 
Bhagat et al. 
(2010) 
No No Yes 10 
Pecora Liberman 
et al. (2011) 
Yes No Yes 15 
Table 1. Recent studies investigating carboplatin ototoxicity in children with 
retinoblastoma,the monitoring methods used, and the number of patients examined. Yes 
indicates the test (behavioral audiometry, ABR, OAE) was evaluated in the study and No 
indicates the test was not evaluated.  
3.1 Behavioral assessment of hearing 
Assessment of infant hearing involves presentation of sounds through loudspeakers and 
observing the infant’s behavior. If a change in behavior (i.e. the infant is startled) occurs 
following presentation of a sound, a positive response is noted. The sound level is lowered 
and the procedure is repeated until no change in behavior is observed. Many infants can 
respond reliably at sufficiently low levels of sound, and this is suggestive of normal hearing. 
However, the response of other infants for similar sound levels may be ambiguous. This 
procedure requires a subjective judgment on whether or not a response has occurred. In 
addition, many infants cease to respond behaviorally after repeated trials, even though they 
may be aware of sound in their environment. For these reasons, response detection levels for 
many infants only provide a gross estimate of hearing sensitivity. However, behavioral 
observation of infant hearing is useful in corroborating the results of physiological screening 
tests. For example, if an infant fails an OAE and/or ABR screening, and does not exhibit a 
behavioral response at sound levels indicative of normal hearing, a hearing loss can be 
confirmed. In addition, observation of developmental auditory behavior in infants can 
provide a guideline for comparative purposes. At three months of age, most normal-hearing 
infants are able to follow the direction a sound is coming from with their eyes. By six 
months of age, they can turn their heads to determine the source of sounds. If an infant 
exhibits delays in development of auditory behavior, a hearing loss may be indicated.  For 
older children, hearing may be assessed by visual reinforcement audiometry (VRA) or 
conditioned play audiometry(CPA). In VRA, a sound is presented through loudspeakers 
and the child is directed to turn their head in the direction of where the sound came from. 
Following a correct response, the child is rewarded by seeing an animated toy. This form of 
reinforcement serves to help the clinician to orient the child to participate in the task and to 
determine the child’s hearing sensitivity. By lowering the sound level until no response is 
provided by the child, the clinician can obtain an estimate of the hearing threshold on a 
frequency-by-frequency basis. In CPA, sounds may be presented through loudspeakers or 
through headphones, and a child is conditioned to drop a block in a bucket (or similar task) 
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every time a sound is heard. Hearing thresholds can be tracked by noting the transitions 
between sound levels where the child performs or does not perform the task. For both VRA 
and CPA, the clinician makes a subjective decision to determine whether or not a response 
occurred, and these methods typically are reserved for children up to 4 years of age. Most 
older children can participate in a conventional hearing test, whereby they raise their hand 
or push a button every time they hear a sound, and their responses are noted on a 
conventional audiogram. 
Platinum-compound ototoxicity typically causes hearing loss at audiometric frequencies 
above 2000 Hz (Macdonald et al., 1994). There are guidelines in place that help to 
characterize shifts in behavioral hearing thresholds on the audiogram due to the 
administration of ototoxic medications. Common guidelines in use to characterize 
ototoxicity in the United States are shown in Table 2. In monitoring ototoxicity, it is vitally 
important to obtain baseline measurements of hearing before the patient undergoes  
 
Brock NCI CTCAE CCG Chang 
Grade 0: 
 < 40 dB at all  
frequencies 
 Grade 0: 
No hearing loss 
Grade 0: 
≤ 20 dB at 1, 2, and 4 
kHz 
Grade 1: 
≥ 40 dB at 
 8 kHz only 
Grade 1: Threshold shift 
or loss of 15-25 dB 
averaged at two 
contiguous frequencies in 
one ear  
Grade 1: 
≥ 40 dB HL loss at  
6 kHz and/or 8 kHz 
Grade 1a: 
≥ 40 dB at any 
frequency from 6-12 
kHz 
Grade 1b: 
>20dB and <40 dB at 4 
kHz 
Grade 2: 
≥ 40 dB at 
 4 kHz and above 
Grade 2: 
Threshold shift or loss 
>25-90 dB averaged at 
two contiguous 
frequencies in one ear 
Grade 2:  
>25 dB HL loss at   
3 kHz and/or 4 kHz
 
Grade 2a: 
≥ 40 dB at 
 4 kHz and above  
Grade 2b: 
>20dB and <40 dB at 
any frequency below 4 
kHz 
Grade 3: 
≥ 40 dB at 
 2 kHz and above 
Grade 3: 
Hearing loss 
sufficient to indicate 
therapeutic intervention, 
including hearing aids 
(e.g. > 20 dB bilateral loss 
in the speech frequencies)
Grade 3:  
>25 dB HL loss at   
2 kHz  
Grade 3: 
≥ 40 dB at 
 2 or 3 kHz and above 
Grade 4: 
≥ 40 dB at 
 1 kHz and above 
Grade 4: 
Indication for cochlear 
implant  
Grade 4:  
 ≥ 40 dB HL loss at  
2 kHz 
Grade 4:  
≥ 40 dB at 
 1 kHz and above 
Table 2. Common grading scales used in the United States for characterizing ototoxic 
hearing loss. dB= decibels, dB HL= decibels hearing level, kHz= kiloHertz.  
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chemotherapy, and then to monitor their hearing at prescribed time points once treatment 
commences. This allows for comparisons to be made between pre-treatment hearing and 
peri- or post-treatment hearing in the patient. The Brock grading scale (Brock et al., 1991) 
assigns a grade based on degree of bilateral hearing loss. The NCI CTCAE (National Cancer 
Institute Common Terminology Criteria for Adverse Events) uses threshold shifts to assign 
its grades based on comparisons between baseline and current hearing thresholds. The CCG 
(Children’s Cancer Group) criteria are based on a loss as defined as a change from baseline 
at any one frequency. The Chang grading scale (Chang & Chinosornvatana, 2010) is the 
most recent of the grading scales that has been developed. 
Clinical studies of carboplatin ototoxicity conducted in children with pediatric cancers other 
than retinoblastoma have revealed equivocal results. Macdonald et al. (1994) found that 50 
% of children in their study had a sensorineural hearing loss in the 4,000-12,000 Hz range 
following treatment with carboplatin. They found that hearing losses could occur after the 
first dose of carboplatin, and that hearing losses could progress with subsequent doses. 
Similarly, Simon et al. (2002) reported that 40% of children treated with high-dose 
carboplatin developed a hearing impairment and Knight et al. (2005) found that 38% of 
children treated with carboplatin developed sensorineural hearing loss. In contrast, Stern 
and Bunin (2002) found that ototoxic complications from carboplatin chemotherapy were 
rare and mild in severity and other studies have found similar results (Bertolini et al., 2004; 
Dean et al., 2008). The variability of carboplatin ototoxicity seen across past studies may be 
related to insufficient control of confounding factors. Factors that may potentiate the 
severity of carboplatin ototoxicity include prior exposure to cisplatin or other ototoxic 
medications and high dosage of carboplatin associated with autologous stem cell reinfusion 
(Knight et al., 2005; Parsons et al., 1998). Another factor that may increase the severity of 
platinum-compound ototoxicity is patient age, with younger children being more  
 
Fig. 1. An audiogram depicting a sensorineural hearing loss in both ears, often seen in 
ototoxicity. The x-axis is frequency in Hertz and the y-axis is level in decibels. The shaded 
region represents the normal-hearing range.  The hearing loss depicted indicates a greater 
loss of sensitivity in the high frequencies compared to the low frequencies.  
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susceptible than older children (Li et al., 2004; Coradini et al., 2007). Studies examining 
carboplatin ototoxicity in children with retinoblastoma are less prevalent. Smits et al. (2006) 
studied 25 children diagnosed with retinoblastoma ranging in age from 1-41 months at the 
start of carboplatin chemotherapy and found no signs of ototoxicity. Lambert et al. (2008) 
reviewed audiometric data from 116 children (aged 1-87 months) treated for retinoblastoma 
with a multi-drug regimen including carboplatin. Most of these children were monitored 
with behavioral audiometry and 48 received ABR evaluations. Only one of the children was 
suspected of incurring progressive hearing loss due to carboplatin chemotherapy, but this 
child was diagnosed at less than 1 month of age. Other studies have also indicated a low 
incidence of carboplatin ototoxicity (4.5-6.6%) in children with retinoblastoma of various 
ages, although some children were found to have late-onset hearing loss (Jehanne et al., 
2009; Pecora Liberman, 2011).  
3.2 Auditory brainstem response 
Behavioral hearing tests in children less than 12 months old can be unreliable and difficult to 
interpret. A common alternative method used to monitor auditory function in children 
receiving platinum-compound chemotherapy is the ABR test. During the ABR test, surface 
electrodes are attached to locations on the scalp and forehead, and these electrodes record 
electrical activity generated by the auditory nerve and neural centers in the brain responsive 
to auditory stimuli. Clicks or brief tones are stimuli presented to an ear while the ABR 
response is being recorded. The ABR test is a passive test in that the patient does not 
respond behaviorally to the sounds that are heard. The electrode leads connect to an 
amplifier box, and the ABR response is filtered and averaged by a computer. The resulting 
ABR waveform consists of a series of positive and negative voltages displayed on a 
computer monitor.  Peak amplitudes and latencies of the ABR waveform are analyzed and 
compared to normative data. The lowest level of sound that can evoke a replicable ABR 
waveform is known as the ABR threshold. Previous research has established that the ABR 
threshold provides a reliable estimation of infant hearing sensitivity. Children with hearing 
loss typically have elevated ABR thresholds compared to children with normal hearing. 
When used as a screening test, a criterion stimulus level is selected and if an ABR waveform 
is successfully recorded at this level, the infant passes the screening test. If an ABR 
waveform is not recorded at the criterion level, a hearing loss may be suspected and the 
infant is referred for further diagnostic testing.  
The ABR screening test is a well-established physiological measurement procedure that has 
been validated through years of clinical research. It is relatively easy to administer and is 
typically completed in a short period of time. However, as with any screening instrument it 
is not infallible. The ABR screening test will produce both false positive (incorrectly failing 
children with normal hearing) and false negative (incorrectly passing children with hearing 
loss) results. Confirmation of hearing loss is often enhanced when test results from OAE 
and/or ABR screenings are combined with reliable behavioral observations of infant 
hearing. In children less than 12 months old, the ABR test may be the only reliable means of 
examining if auditory function is being compromised by carboplatin, given that younger 
children receiving platinum compounds may be more susceptible to drug-induced hearing 
loss as estimated by ABR thresholds (Coupland et al., 1991). Previous research has shown 
that click-evoked ABR test results can accurately track permanent changes in cochlear 
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function due to administration of ototoxic medications in adults (DeLauretis et al.,1999). 
However, some studies have questioned the sensitivity of ABR test results in monitoring 
platinum-compound ototoxicity in children (Weatherly et al., 1991). It is known that 
carboplatin can cause a substantial amount of damage to inner hair cells and spiral ganglion 
neurons prior to a change being registered on an electrophysiological assessment, such as 
the compound action potential (El-Badry & McFadden, 2007). Because the ABR is a far-field 
potential that relies upon compound activity from an ensemble of neurons, it may not 
provide the best indication of early change in cochlear function. In addition, if a change is 
detected on the ABR test, it may reflect a permanent loss of auditory sensitivity. 
3.3 Otoacoustic emissions 
An alternative method of monitoring platinum-compound ototoxicity is the OAE test. 
Believed to be linked to the functional status of outer hair cells (Brownell, 1990), OAEs have 
been effectively used to monitor platinum-compound ototoxicity in children ( Dhooge et al., 
2006; Knight et al., 2007). OAEs are usually inaudible sounds produced by the healthy inner 
ear, and these sounds escape into the ear canal and are measured with an ear-canal probe 
containing a miniature microphone. The probe assembly interfaces with a computer, and a 
software program analyzes data being recorded by the probe microphone. Typically, OAEs 
are evoked by stimulating the ear with clicks or tones, and the recorded response is then 
measured and compared to normative data collected in children with normal hearing. No 
overt behavioral response from the child is required, and the test can be done while the 
child is asleep. This physiological test provides information on the functional status of 
middle and inner ear (outer hair cells) structures. Children with hearing loss have reduced 
or absent OAEs compared to normal-hearing children. A criterion OAE response is required 
in order to pass the test, and children who fail are typically referred for further testing to 
confirm potential hearing loss. The OAE test is a simple screening test to administer and can 
be completed rapidly, typically within 1-2 minutes per ear. However, a relatively quiet 
environment is required to complete a valid OAE test, as extraneous noise recorded by the 
probe microphone can interfere with testing. In addition, the degree of hearing loss cannot 
be determined by OAE testing alone, as both hard-of-hearing and deaf children typically 
exhibit absent OAE responses. The information provided by OAE testing is quite useful in 
determining if a child is a potential candidate for intervention programs.  
In children, OAEs were found to be reduced prior to the onset of hearing loss on the 
audiogram in the conventional frequency range following cisplatin chemotherapy (Knight et 
al., 2007). DPOAE levels also exhibit high correlations with behavioral hearing thresholds in 
children suffering hearing loss due to platinum compound ototoxicity (Dhooge et al., 2006). 
High doses of carboplatin are known to damage outer hair cells and reduce the amplitude of 
OAEs in animal model (Hofstetter et al., 1997b). Based on these findings, the OAE test 
potentially is more sensitive at detecting early changes in cochlear function due to 
carboplatin ototoxicity than is the ABR test. Previous research has not compared the abilities 
of ABRs and OAEs to register changes in cochlear function throughout the entire course of 
carboplatin chemotherapy in young children with retinoblastoma. In fact, few studies have 
examined OAE tests in children with retinoblastoma.  Smits et al. (2006) examined OAEs in 
evaluating children with retinoblastoma receiving carboplatin. They concluded that there 
were no signs of ototoxicity in the sample of children they examined, although no details 
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concerning what constituted a change in OAE level were provided. Bhagat et al. (2010) 
found different results in studying 10 children with retinoblastoma receiving carboplatin. 
They reported that when a criterion change in OAE level was utilized, four of the ten 
children studied had reductions in OAE level that met the criterion. These findings suggest 
that OAE tests are useful in identifying the deleterious effects of carboplatin chemotherapy 
on cochlear function in some children with retinoblastoma.  
 
Fig. 2. Mean OAE levels in children with retinoblastoma before (open triangles) and after 
(filled triangles) carboplatin chemotherapy. Post-therapy OAE levels at the highest test 
frequency were reduced compared to pre-therapy OAE levels. Reprinted from the 
International Journal of Pediatric Otorhinolaryngology, Vol. 74/Issue 10, Bhagat, S.P., Bass, 
J.K., White, S.T., Qaddoumi, I., Wu. J. & Rodriguez-Galindo, C., “Monitoring carboplatin 
ototoxicity with distortion-product otoacoustic emissions in children with retinoblastoma”, 
pp.1156-1163, 2010, with permission from Elsevier. 
4. Impact of hearing loss on academic and social development 
The degree of hearing loss associated with carboplatin ototoxicity can vary, but the initial 
onset of hearing loss typically begins in the high frequencies. High-frequency sensorineural 
hearing loss can be problematic for the development of speech and language in young 
children (Stelmachowicz et al., 2004). High frequency speech phonemes contribute to speech 
intelligibility, and high frequency sensorineural hearing loss reduces the audibility of 
important speech cues, limits speech understanding in noise, and increases the risk for 
academic failure (Stelmachowicz et al., 2001; Horwitz et al., 2002; Bess et al., 1998). With 
more courses or higher dosages of carboplatin, hearing may deteriorate further, and the 
hearing loss may involve a loss of sensitivity at lower frequencies on the audiogram 
(Parsons et al., 1998). In rare cases, the use of platinum compounds may result in deafness 
(Chu et al., 1993).  
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In most educational settings, the dominant mode of information transfer from teacher to 
student is oral instruction. Most normal-hearing children have little difficulty understanding 
oral instruction and have developed a sufficient language base to successfully progress 
academically. However, children with permanent sensorineural hearing loss are at a 
disadvantage compared to their normal-hearing peers. Oral instruction may be inaudible to 
hearing-impaired students, depending upon the degree of hearing loss. In addition, hearing-
impaired students often lack language skills that are requisite for achievement in the 
classroom. While advancements in technology have increased the audibility of classroom 
instruction for many hearing-impaired students, their expressive and receptive language 
skills are often below those of children with normal hearing. These language skills form the 
foundation for word knowledge and verbal reading, which account for 90% of the 
variability in reading skills found in normal hearing children (Davis, 1972). The lack of an 
adequate language base in both hard-of-hearing and deaf children impacts their academic 
performance. Average reading ability for hard-of-hearing high school graduates has been 
measured at the fifth-grade level, while average reading ability for deaf high school 
graduates was at the fourth-grade level. Reading ability for both groups was below that of 
their normal-hearing peers (Allen, 1986). The overall academic performance of hearing-
impaired students is negatively influenced by their reading ability (Quigley, 1979). 
Once suspected, hearing loss in infants is confirmed through diagnostic tests. The degree of 
hearing loss can be determined with diagnostic physiological tests such as the ABR 
combined with behavioral auditory assessments. This information is important, as the type 
of intervention planned often depends on whether the infant is hard-of-hearing or deaf. 
Traditional amplification systems, including hearing aids, usually can benefit hard-of-
hearing children (Gravel & O’Gara, 2003). When their residual hearing is aided and they are 
able to hear the acoustic cues of conversational speech, the language acquisition of hard-of-
hearing children can be similar to that of normal-hearing children (Moeller, 2000). Factors 
which influence the language skills of hard-of-hearing children include the age at which 
their hearing loss was identified, when they received intervention and the amount of 
parental involvement in the intervention plan (Yoshinaga-Itano et al.,1998; Yoshinaga-Itano 
& Apuzzo, 1998). 
For many deaf children, traditional amplification systems may not be a viable option. These 
children often do not have enough residual hearing to benefit from hearing aids. Alternative 
intervention in the form of cochlear implants designed to facilitate development of spoken 
language, or adoption of manual communication as the child’s first language may be more 
appropriate options. The choice of which communication style to adopt for a deaf child can 
be a controversial one for many families. This choice can be influenced by the opinions of 
intervention professionals, who often view deafness as a condition to fix. However, 
individuals in the Deaf community have argued that deafness is indicative of a cultural 
difference, and that all deaf children should learn American Sign Language as their primary 
means of communication (Samson-Fang et al., 2000). The choice of communication style will 
certainly affect the future educational placement of the deaf child. Deaf children who receive 
cochlear implants are more likely to be mainstreamed with normal-hearing children in 
classrooms, while alternative educational placements may be required for children who 
communicate manually. Regardless of the communication style, evidence indicates that 
early intervention benefits linguistic outcomes. Children who receive cochlear implants 
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within the age range of 2-6 years perform well on speech reception and production tasks, 
with better performance seen in children implanted earlier rather than later in life (Brackett 
& Zara, 1998). Deaf children with early exposure to manual communication developed 
linguistic skills in a manner similar to normal-hearing children who received early exposure 
to spoken language (Bandurski & Galkowski, 2004). These findings underscore the 
importance of early intervention on the development of hearing-impaired children. 
Substantial evidence concerning the effects of early identification of hearing loss and early 
intervention on the language development of hearing-impaired children has been provided 
by Yoshinaga-Itano and her colleagues. In a series of studies published in peer-reviewed 
journals, they examined the language skills of children between 13-40 months of age who 
were identified with hearing loss either before or after the age of six months. The expressive 
and receptive language development of children enrolled in intervention services before six 
months of age was significantly better than those of the children identified later in life. Both 
hard-of-hearing and deaf children benefited from early intervention. Most importantly, the 
language skills of the early-identified children approached those seen in age-matched 
normal-hearing children (Yoshinaga-Itano et al., 1998; Yoshinaga-Itano & Apuzzo, 1998). 
Moeller (2000) extended these results, finding that the benefits of early intervention on 
language development were maintained in children at five years of age. In addition, 
personal-social development and self concept are more advanced in children who were 
identified and enrolled in intervention early in life (Yoshinaga-Itano, 2003).  
Another contributing factor to the development of language in hearing-impaired children is 
the degree of family involvement in the intervention plan (Moeller, 2000). The diagnosis of 
hearing loss in an infant can be a catastrophic event in the emotional lives of new parents. 
Parental reaction to this event can contribute significantly to the developmental outcomes 
for the child (Kurtzer-White & Luterman ,2003). Once they are informed about their child’s 
hearing loss, many parents go through a series of emotions including anger, resentment, and 
guilt before acceptance of the hearing loss occurs. Recognition of these coping mechanisms 
by professionals including physicians and educators will enhance parental involvement in 
the intervention process. There is evidence that well-adjusted families contribute to 
academic achievement in hearing-impaired children (Feher-Prout, 1996). Educators of the 
deaf have received training in psychosocial issues of hearing-impaired children and their 
families, and this expertise can improve the quality of early intervention services. 
5. Otoprotection and carboplatin-induced hearing loss 
The ability to prevent ototoxicity in patients undergoing carboplatin chemotherapy with 
pharmaceutical agents is currently being investigated by several teams of researchers. The 
molecular mechanisms of cell death in the cochlea induced by ototoxic agents are currently 
being elucidated. Armed with this knowledge, researchers are developing substances that 
can interrupt the chain of events that lead to hearing loss. These substances are generally 
known as “otoprotectants”. Sodium thiosulfate (STS) is an otoprotectant used to prevent 
carboplatin ototoxicity that has been evaluated in animal models and in human patients. In 
guinea pigs, STS was found to reduce the toxicity of carboplatin when it was given up to 8 
hours after the ototoxic drug was administered (Neuwelt et al., 1996). Further, the ability of 
STS to lessen the cochlear toxicity of carboplatin did not interfere with the anti-tumor 
effectiveness of carboplatin in rats (Muldoon et al., 2000). In a study involving human 
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patients receiving carboplatin, Neuwelt et al. (1998) found that patients given STS 2 hours 
after carboplatin administration incurred a significantly lower average hearing loss 
compared with a control group of patients that did not receive STS. The benefits of delayed 
administration of STS were further revealed when it was shown that when STS is given 4 
hours after carboplatin, it reduces ototoxicity rates (Doolittle et al., 2001). The beneficial 
effects of STS in adults were also seen in a study involving children, where trends indicated 
that STS provided protection against carboplatin ototoxicity while sparing the anti-tumor 
activity of the drug (Neuwelt, 2006). Another otoprotectant against carboplatin ototoxicity 
that has been evaluated in animal models is D-Methionine (D-Met). Lockwood et al. (2000) 
found that carboplatin-induced cell loss was reduced in chinchillas treated with D-met 
compared to untreated controls.  
In the future, it is conceivable that otoprotectants such as STS or D-Met would be 
administered during carboplatin chemotherapy in order to reduce the cochlear toxicity of 
the drug. The use of these pharmaceutical agents to prevent hearing loss would be 
invaluable in children with retinoblastoma, as these children have existing visual 
impairments in one or both eyes.  
6. Conclusions 
Carboplatin is a chemotherapy agent with known ototoxic side effects that is widely used in 
the conservative management of retinoblastoma. Children with retinoblastoma have visual 
impairments that may impact their development. There is a risk of incurring additional 
sensory deficits (loss of hearing) when carboplatin is included in the treatment regimen. 
Although research to date has indicated a low incidence of carboplatin-induced hearing loss 
in children with retinoblastoma, additional study of this topic is required before definitive 
conclusions can be drawn. Factors such as exposure to other ototoxic agents including 
cisplatin and poor renal function may potentiate carboplatin-induced hearing loss. It is 
important that medical professionals remain vigilant about monitoring hearing during 
carboplatin chemotherapy, as conservation of hearing is a priority in children with 
retinoblastoma. If a change in hearing is noted during the monitoring regimen, it may be 
possible to alter the dosage of the drug to prevent further deterioration in hearing from 
occurring. If the carboplatin dose cannot be modified, monitoring hearing status during the 
treatment regimen can serve as an entry point into intervention programs, including the 
provision of hearing aids and family counseling. It is also important to note that late-onset 
hearing loss can occur years after completion of carboplatin chemotherapy. Therefore, long-
term hearing assessments may be required in these cases. Recognition of the impact of 
ototoxic hearing loss on the lives of retinoblastoma survivors will lead to appropriate 
planning in cases when hearing loss is detected.  
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